3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
170
Rituximab
164
Specimen Handling
116
Biopsy
92
Magnetic Resonance Spectroscopy
90
Vincristine
86
Doxorubicin
81
Prednisone
78
fludarabine
70
venetoclax
69
obinutuzumab
62
ibrutinib
55
Lenalidomide
55
Dexamethasone
55
Cytarabine
49
Methotrexate
47
acalabrutinib
44
Etoposide
43
CT-P10
42
blinatumomab
38
fludarabine phosphate
35
Bendamustine Hydrochloride
34
Gemcitabine
33
zanubrutinib
31
prednylidene
31
pembrolizumab
30
glofitamab
30
deltacortene
30
Calcium Dobesilate
30
Nivolumab
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cobicistat
×
Lymphoid
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA